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Abstract
Background
Underlying medical causes of obesity (endocrine disorders, genetic obesity disorders, cere-
bral or medication-induced obesities) are thought to be rare. Even in specialized pediatric
endocrinology clinics, low diagnostic yield is reported, but evidence is limited. Identifying
these causes is vital for patient-tailored treatment.
Objectives
To present the results of a systematic diagnostic workup in children and adolescents
referred to a specialized pediatric obesity center.
Methods
This is a prospective observational study. Prevalence of underlying medical causes was
determined after a multidisciplinary, systematic diagnostic workup including growth charts
analysis, extensive biochemical and hormonal assessment and genetic testing in all
patients.
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Results
The diagnostic workup was completed in n = 282 patients. Median age was 10.8 years (IQR
7.7–14.1); median BMI +3.7SDS (IQR +3.3-+4.3). In 54 (19%) patients, a singular underly-
ing medical cause was identified: in 37 patients genetic obesity, in 8 patients cerebral and in
9 patients medication-induced obesities. In total, thirteen different genetic obesity disorders
were diagnosed. Obesity onset <5 years (p = 0.04) and hyperphagia (p = 0.001) were indica-
tors of underlying genetic causes, but only in patients without intellectual disability (ID).
Patients with genetic obesity with ID more often had a history of neonatal feeding problems
(p = 0.003) and short stature (p = 0.005). BMI-SDS was not higher in patients with genetic
obesity disorders (p = 0.52). Patients with cerebral and medication-induced obesities had
lower height-SDS than the rest of the cohort.
Conclusions
To our knowledge, this is the first study to report the results of a systematic diagnostic
workup aimed at identifying endocrine, genetic, cerebral or medication-induced causes of
pediatric obesity. We found that a variety of singular underlying causes were identified in
19% of the patients with severe childhood obesity. Because of this heterogeneity, an exten-
sive diagnostic approach is needed to establish the underlying medical causes and to facili-
tate disease-specific, patient-tailored treatment.
Introduction
Obesity is a multifactorial disease that has become one of the greatest health challenges of our
time. [1] The prevalence of severe obesity in children and adolescents (as defined by the World
Health Organization [2] and the International Obesity Task Force [3]; IOTF) was recently
shown to range from 1.7% to 6.3% in several countries. [4] Body mass index is strongly influ-
enced by genetic susceptibility with an estimated heritability of 40–70%. [5, 6] Most children
and adolescents with obesity do not have singular underlying medical disorders causing their
obesity, such as endocrine disorders, genetic obesity disorders, cerebral or medication-related
causes. [7] The pathophysiologic mechanisms of the underlying medical conditions causing
obesity are widely varied, leading to the suggestion to talk about “different diseases causing
obesity” or “obesities”. [8] Establishing an underlying diagnosis can give insight into the clini-
cal course of the obesity, and lead to tailored monitoring and treatment. [9] In addition, it
ends the diagnostic odyssey and can reduce the stigma that patients are confronted with. [10,
11] Since pharmacological treatment for patients with genetic defects affecting the leptin-mela-
nocortin pathway (the hypothalamic system that controls appetite and energy expenditure)
[11] is currently being evaluated in clinical trials, identifying these diseases becomes even
more relevant. [8, 12] It is difficult to assess which patients should be evaluated for underlying
causes. The current international clinical practice guideline for the evaluation and treatment
of pediatric patients with obesity was published in 2017 by the Endocrine Society (ES). [13] In
this guideline, clinicians are guided through the diagnostic process. After medical history-tak-
ing and physical examination, specific additional diagnostic steps are suggested depending on
the findings. In short, endocrine evaluation is recommended in patients with reduced growth
velocity; evaluation of hypothalamic obesity in patients with central nervous system (CNS)
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injury, and re-evaluation of drug choice in patients using antipsychotic drugs. In selected
cases, genetic testing is recommended, e.g., in patients displaying extreme early-onset obesity
(<5 years) and severe hyperphagia, which are considered cardinal features of genetic obesity
disorders. The genetic tests mentioned in the guideline range from karyotyping to DNA diag-
nostics for deficiencies in the leptin-melanocortin pathway. As of yet, studies that systemati-
cally screen for the underlying medical causes mentioned in the ES guideline in children and
adolescents with obesity have not been performed. Previous studies on genetic obesity disor-
ders report an underlying causative genetic defect in 2–5% of non-consanguineous pediatric
patients with severe obesity, [13–15] but prevalence of the other underlying medical causes of
obesity has not been studied. Therefore, our primary aim was to analyze the results of a thor-
ough diagnostic workup in a cohort of patients who had been referred to the pediatric division
of a specialized tertiary obesity center. Our diagnostic approach included broad evaluation for
each patient of all possible underlying medical causes of obesity as mentioned in the ES guide-
line: endocrine and genetic disorders, as well as cerebral injury and medication use. Moreover,
we compared the detailed clinical phenotype of these patients to evaluate whether the patients
with underlying medical causes of obesity can be distinguished from those without an underly-
ing medical cause.
Methods
For this analysis, medical data of children and adolescents aged 0–18 years visiting Obesity
Center CGG (Dutch: Centrum Gezond Gewicht; English: Centre for Healthy Weight) were ana-
lyzed. Obesity Center CGG is a Dutch multidisciplinary referral center for obesity consisting
of a collaboration between the departments of Pediatrics, Internal Medicine and Surgery of the
academic hospital Erasmus MC and collaborating general hospitals Maasstad Ziekenhuis and
Franciscus Gasthuis. In this prospective, observational study, informed consent was obtained
at the initial visit according to Dutch law: written informed consent was obtained from parents
and children >12 years; for children below age 12 years oral assent was additionally obtained.
This also included separate consent forms for genetic testing. The study was approved by the
medical ethics committee of the Erasmus MC (MEC-2012-257). Pediatric patients were
referred to Obesity Center CGG for diagnostic evaluation (due to suspicion of underlying
causes of obesity, severe obesity, or resistance to combined lifestyle intervention), personalized
therapeutic advice, or participation in a combined lifestyle intervention (Fig 1). [16] All conse-
cutive patients who provided written informed consent were included at the university medi-
cal center Erasmus MC-Sophia Children’s Hospital from 2015 to August 2018. From 2016 to
August 2018, the collaborating general hospital Maasstad Ziekenhuis also included patients
with a suspicion of an underlying medical cause of obesity. Exclusion criteria for this study
were inability or refusal to give informed consent, refusal to undergo genetic testing, or not
completing the standardized diagnostic approach (Fig 1). A standardized diagnostic approach
was applied for all patients (Fig 2), discussed below and in more detail in the S1 Appendix,
aimed at identifying underlying endocrine, genetic, cerebral, and medication-induced main
causes of obesity. At study entry, medical history-taking, physical examination and extensive
assessment of growth charts were performed by a pediatric endocrinologist or pediatrician
supervised by a pediatric endocrinologist. A few weeks after the initial visit, patients returned
to the outpatient clinic where blood was drawn after an overnight fast for biochemical and hor-
monal evaluation, and genetic diagnostics. All patients and/or their parents were asked to fill
out several questionnaires regarding physical activity, eating behavior, sleeping behavior,
stress, and quality of life. Furthermore, all patient records were screened by a clinical geneticist.
In case of high suspicion of genetic obesity or abnormal genetic test results, patients were seen
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by a clinical geneticist at the outpatient clinic. Patients who visited the academic center were
also seen by a pediatric physiotherapist, pedagogist, and pediatric dietician. Additional diag-
nostics (i.e., further genetic testing, neuropsychological or radiologic assessments) were per-
formed when clinically indicated following international clinical guidelines. After the
diagnostic procedure, it was assessed for each patient whether an endocrine, genetic, cerebral
or medication-induced main underlying cause of obesity could be diagnosed. Contributing
factors to weight gain (e.g. sleep deprivation, screen time) were not considered as main
Fig 1. Study flow chart. Flow chart indicating the inclusion of participants and diagnoses established in our cohort.
Abbreviations: CGG, Dutch: Centrum Gezond Gewicht; English: Centre for Healthy Weight; ID, intellectual disability.
https://doi.org/10.1371/journal.pone.0232990.g001
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underlying causes of obesity. After the diagnostic workup, a patient-tailored treatment plan
was designed by the multidisciplinary team in which all relevant findings were incorporated,
including advice regarding diet and physical activity, medical treatment (regarding comorbidi-
ties) or referral to combined lifestyle intervention, parent support center, psychologist, or psy-
chiatrist. This personalized treatment plan was discussed with the patient and parents and
tailored to their personal situation and needs.
Assessments
The features that were assessed during the diagnostic workup are summarized below (details
in the S1 Appendix).
Phenotypic features. Clinical history-taking and physical examinations were performed
following the Dutch pediatric obesity guideline, including evaluation of neonatal feeding,
weight-inducing medication use, development, dysmorphic features, or congenital anomalies.
[17] Height, weight and head circumference were measured rounded to the nearest decimal.
The Dutch national growth charts, which use the definition of pediatric obesity by Cole et al.,
were used to calculate standard deviation scores (SDS). [3, 18] Severe obesity was defined by
the IOTF definition as a BMI� the age- and sex-specific IOTF BMI-values corresponding to a
BMI of 35 kg/m2 at age 18 years. [3] Each patient’s growth charts were studied in detail to
determine the age of onset of obesity and to evaluate the presence of sudden weight changes. If
sudden weight changes were present, it was determined whether these changes were associated
with cerebral injury (e.g., tumor in the hypothalamic region) or use of known weight-inducing
medication. Short stature was defined as a height-for-age z-score <2 SDS or height-for-age
<-1.6 SDS compared to target height; [19] tall stature as a height-for-age z-score>2 SDS or
height-for-age >2 SDS compared to target height. [20] Intellectual disability was determined
by the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5) definition of intellec-
tual disability or an IQ score�70. Family histories of bariatric surgery and extreme obesity
Fig 2. Diagnostic approach. Systematic diagnostic approach for children and adolescents with obesity and a suspicion of an underlying medical cause.
Abbreviations: OGTT, oral glucose tolerance test; IGF-1, Insulin-like growth factor 1; GP, general practitioner.
https://doi.org/10.1371/journal.pone.0232990.g002
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(BMI> 40 kg/m2 for adults, or corresponding pediatric value) [3] were obtained for the past
three generations. Information on consanguinity was obtained from questionnaires and addi-
tionally from the regions of homozygosity identified by SNP microarray analysis (see below).
Presence of hyperphagia was determined by the physician, based on the child’s or parents’
answers regarding hunger, e.g., satiation and satiety, preoccupation with food, night eating,
secret eating, food-seeking behavior, and the distress that accompanies the child’s hunger or
obsession with food. [21] Patients were considered Dutch if patient and both parents were
born in The Netherlands; otherwise, patients were classified as having a migration back-
ground. [22] Presence of psychosocial/psychiatric problems was defined as the presence of an
established DSM-5 diagnosis (with the exception of intellectual disability) or social problems
for which official authorities were involved, such as child protective services. Additionally,
Dutch neighborhood socioeconomic status z-scores were calculated. These summarize average
income, education and unemployment in postal code areas to provide an estimate of the socio-
economic status of patients. [23] Finally, the contribution of lifestyle factors was assessed. As
lifestyle factors play a role in every case of obesity, the multidisciplinary team determined if
lifestyle factors were the most important contributor to the obesity for each patient without an
underlying medical diagnosis. For example, this label determination was used for patients
without an underlying medical diagnosis who reported that obesity started during the divorce
of their parents and consequently never resolved. This was subsequently objectified in their
growth charts.
Laboratory assessment. Laboratory assessment was performed for all patients. These con-
sisted of screening for comorbidities of obesity, including standard oral glucose tolerance test,
lipids, liver enzymes, vitamin D status and hormonal assessment, i.e., thyroid hormones, corti-
sol, insulin-like growth factor 1, androgens, and leptin. Further details are provided in the S1
Appendix.
Genetic testing. Obesity gene panel sequencing and single nucleotide polymorphism
(SNP) microarray analysis were performed in a diagnostic setting for all patients. Three diag-
nostic obesity gene panel tests successively became available in The Netherlands during the
time span of the study (S1 Appendix). All patients were tested at least for the most important
genetic obesity disorders mentioned in the ES guideline, such as GNAS, LEP, LEPR, MC4R,
PCSK1, POMC, and SIM1. [13] Details and complete gene lists are provided in the S1 Appen-
dix. Obesity gene panel sequencing was performed in the ISO 15189 accredited genetic diag-
nostics laboratories of Amsterdam UMC and UMC Utrecht. Chromosomal microarray
analysis and additional diagnostic tests were also performed at the ISO 15189 genetic diagnos-
tics laboratories of other Dutch academic centers. Identified variants were compared with in-
house and public databases to exclude common variants. Variants were classified according to
the American College of Medical Genetics and Genomics (ACMG) guideline. [24] Family seg-
regation studies were performed if necessary to clarify the pathogenicity of a variant of uncer-
tain significance (VUS) or copy number variation (CNV). Interpretation of found variants was
performed in a diagnostic setting according to the ACMG guideline. Variants of uncertain sig-
nificance were not classified as genetic obesity disorder, but as a VUS/CNV that possibly
explains the obesity phenotype, for which functional studies or other evidence for pathogenic-
ity are necessary. All patients were evaluated by a clinical geneticist specialized in genetic obe-
sity disorders to see whether further genetic testing (e.g., Prader-Willi syndrome (PWS) and
Temple syndrome diagnostics, whole exome sequencing) was warranted, for example in case
of unexplained intellectual disability, short stature, neonatal hypotonia, multiple congenital
anomalies or other signs and symptoms of genetic obesity disorders as mentioned in the ES
guideline. [13]
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Definition of underlying medical causes of obesity. We used the following definitions of
main underlying medical causes of obesity:
Genetic obesity was diagnosed when genotyping revealed known pathogenic variants in
obesity-associated genes which matched the clinical phenotype. Likely pathogenic variants, as
defined by the American College of Medical Genetics and Genomic (ACMG) guideline, [24]
were only considered as causative if the clinical phenotype of the patient matched with the
found genotype (according to the clinical features mentioned in the ES guideline) [13] and seg-
regation analysis was indicative as well. For genetic obesity disorders not mentioned in the ES
guideline, the typical phenotype was based on literature review. [25–32]
Endocrine obesity: Cushing’s syndrome and clinical hypothyroidism were considered
endocrine causes of obesity. Additional diagnostics for Cushing’s syndrome were performed
in the presence of impaired growth velocity coinciding with sudden weight gain, Cushingoid
phenotype features, and abnormal laboratory results. [13, 33]
Cerebral injury was diagnosed as the cause of obesity in the presence of CNS injury affect-
ing the hypothalamic centers for weight regulation due to craniopharyngioma surgery, menin-
gitis or ischemic damage, coinciding with a sudden progression of obesity (seen as a clear
visual slope discontinuity in the growth curve from the time of CNS injury onwards) and the
absence of other plausible explanations for the sudden weight gain.
Medication-induced obesity was diagnosed in the presence of start or intensification of
known weight-inducing medication (i.e., corticosteroids, anti-epileptic, anti-depressant and
anti-psychotic drugs) [34–38] coinciding with a sudden progression of obesity (seen as a clear
visual slope discontinuity in the growth curve) and the absence of other plausible explanations
for the sudden weight gain.
Analysis
Statistical analysis was performed using SPSS version 24.0 [IBM Corp. Armonk, NY]. Data are
presented as median (interquartile range; IQR) and maximum, or mean (standard deviation;
SD) and maximum, as appropriate. Differences in features between patients with genetic obe-
sity disorders and patients without a singular underlying medical cause of obesity were ana-
lyzed using the chi-squared test, Fisher’s exact test, independent sample t-test or Mann-
Whitney U test, as appropriate. Two-sided p-values <0.05 were considered statistically signifi-
cant, as we interpreted these comparisons as hypothesis-generating. For the same reason, we
decided not to perform formal statistical testing for comparisons between other patient sub-
groups due to the small subgroup sizes.
Results
Patient characteristics
In total, 347 patients were referred to Obesity Center CGG during the time span of this study
(Fig 1). Of these patients, 282 patients underwent the complete diagnostic workup and were
included in these analyses. The majority of these patients presented at the academic hospital
(222; 78.7%). Most patients were referred because of suspicion of an underlying cause (Fig 1).
All 282 patients underwent the described gene panel analysis and chromosomal microarray
analysis. After consulting with a clinical geneticist, additional genetic diagnostics were per-
formed for 77 patients. The most important modalities were PWS diagnostics in 31 patients;
whole exome sequencing in 27 patients; maternal UPD14 diagnostics in 21 patients. Median
BMI for age was +3.7 SDS (IQR +3.3-+4.3), indicating severe obesity (Table 1). Most patients
were Dutch (183/282, 64.9%); 99/282 (35.1%) had a migration background. In 67/282 (23.8%)
of the patients intellectual disability (ID) was present.
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Underlying medical causes of obesity
An underlying medical cause of obesity was identified in 54/282 (19.1%) patients in our
cohort: 37 genetic obesity disorders, 9 medication-induced obesities, and 8 obesities due to
cerebral injury (Table 1). None of the patients’ obesity was explained by clinical hypothyroid-
ism or Cushing’s disease. In the remaining 228/282 (80.9%) patients no singular underlying
medical cause of obesity could be identified. In 17 of these 228 patients a VUS/CNV [24] was
identified that possibly explains the obesity phenotype, but this still requires further research,
such as functional studies, and therefore falls beyond the scope of this article.
Genetic causes
Of the 37 patients with genetic obesity, 18 patients had a genetic obesity disorder with ID, and
19 without ID. Pathogenic variants in MC4R were the most commonly found genetic obesity
disorder in our cohort and were found in 9/37 patients, corresponding to 3.2% of the total
cohort of 282 patients. The second frequently identified genetic obesity disorders were biallelic
LEPR pathogenic variants (6/37), followed by GNAS pathogenic variants leading to pseudohy-
poparathyroidism type 1a (5/37). The specific genetic aberrations are presented in Table 2.
The clinical phenotypes of all patients with genetic obesity are described in Tables 3 and 4.
Although most patients with a genetic obesity disorder had a combination of clinical features
typical of their genetic obesity disorder, most patients did not have the complete clinical pheno-
type as mentioned in the ES guideline (Tables 3 and Table 4). Most notably, 6 out of 18 patients
who were diagnosed with a genetic obesity disorder that is typically associated with ID did not
have ID or developmental delay (Table 3).
In 3/37 cases, a heterozygous mutation/CNV was identified (in 2 patients in POMC and in
1 patient in PCSK1), which constitutes important genetic risk factors for early-onset obesity as
demonstrated in association studies, [27, 39] in contrast to their autosomal recessive forms
which cause a more severe clinical phenotype (S1 Appendix).
Cerebral injury as cause of obesity
We identified cerebral injury as the underlying medical cause of obesity in 8/282 (3%) patients.
In five patients onset of rapid weight gain, objectified through analysis of their growth charts,
coincided with intracranial surgery and/or radiotherapy (two craniopharyngiomas and three
malignancies in the hypothalamic region). One patient had congenital anatomic midline
defects in the hypothalamic region and clear hyperphagia and excessive weight gain from
birth. In the remaining two patients onset of rapid weight gain occurred after meningitis or
ischemic infarction, suggesting hypothalamic dysfunction.
Use of known weight-inducing medication as cause of obesity
In 9/282 patients (3%) medication-induced obesity was diagnosed through the combination of
extensive evaluation of their growth charts and medication history and exclusion of endocrine,
genetic, or cerebral causes of obesity. Of these nine patients, six were chronic users of inhala-
tion corticosteroids (ICS). In 5/6 patients, periods of sudden weight gain, as seen on their
growth charts, coincided with intermittent use of oral corticosteroids in the absence of other
plausible causes of their sudden weight gain. In the remaining patient periods of intensification
of chronic ICS use coincided with sudden weight gain according to the growth chart, without
other plausible explanations for the sudden weight gain. In the other three patients the start
and restart of antipsychotic drugs in one, and antiepileptic drugs in two patients, coincided
with sudden weight gain.
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Table 2. Overview of genetic alterations in patients diagnosed with a genetic obesity disorder.
Patient Gene/CNV Reference
transcript
Genetic alteration Inheritance
Genetic obesity disorders without ID
1 MC4R NM_005912.2 Heterozygous c.105C>A p.(Tyr35�) M
2 MC4R NM_005912.2 Homozygous c.216C>A p.(Asn72Lys) n.p.
3 MC4R NM_005912.2 Heterozygous c.105C>A p.(Tyr35�) M
4 MC4R NM_005912.2 Compound heterozygous c.446_450del p.(Phe149Tyrfs�9), c.644T>G p.
(Met215Arg)
P and M both
heterozygous
5 MC4R NM_005912.2 Homozygous c.779C>A p.(Pro260Gln) P and M both
heterozygous
6 MC4R NM_005912.2 Heterozygous c.913C>T p.(Arg305Trp) de novo
7 MC4R NM_005912.2 Heterozygous c.380C>T p.(Ser127Leu) P
8 MC4R NM_005912 Heterozygous c.750_751del p.(Ile251Trpfs�34) n.p.
9 MC4R NM_006147.2 Homozygous c.785del p.(Phe262Serfs�4) n.p.
10 LEPR NM_001003679.3 Compound heterozygous c.2168c>T p.(Ser723Phe), c.1985T>C p.
(Leu662Ser)
P and M both
heterozygous
11 LEPR NM_001003679.3 Compound heterozygous c.2051A>C p.(His684Pro), c.2627C>A p.
(Pro876Gln)
P and M both
heterozygous
12 LEPR NM_002303.5 Compound heterozygous c.1753-1dup p.?, c.2168C>T p.(Ser723Phe) P and M both
heterozygous
13 LEPR NM_002303.5 Homozygous c.1604-8A>G p.? intronic pathogenic variant affecting splicing P and M both
heterozygous
14 LEPR NM_002303.5 Homozygous c.3414dup p.(Ala1139Cysfs�16) P and M both
heterozygous
15 LEPR NM_002303.5 Compound heterozygous c.1835G>A p.(Arg612His), c.2051A>C p.
(His684Pro)
P and M both
heterozygous
16 PCSK1 NM_000439.4 Heterozygous c.541T>C p.(Tyr181His)a M
17 POMC NM_001035256.1 Heterozygous c.706C>G p.(Arg236Gly)a n.p.
18 SIM1 n/a 6q16.3 deletion (chr6:100.879.864–102.471.598), disrupting SIM1 de novo
19 STX16 (PHP 1b) NM_003763.5 Heterozygous microdeletion c.331-?_585 + ? p.? M
Genetic obesity disorders with ID
1 GNAS (PHP1a) NM_001077488 Heterozygous c.85C>T p.(Gln29�) M
2 GNAS (PHP1a) NM_000516.4 Heterozygous c.794G>A p.(Arg265His) M
3 GNAS (PHP1a) NM_018666.2 Heterozygous c.665T>C p.(Met222Thr)b M and PM
4 GNAS (PHP1a) NM_018666.2 Heterozygous c.665T>C p.(Met222Thr)b M and PM
5 GNAS (PHP1a) NM_018666.2 Heterozygous c.665T>C p.(Met222Thr)b M and PM
6 16p11.2del n/a Distal 16p11.2 deletion (chr16:28,825,605–29,043,450, incl. SH2B1) P and MP
7 16p11.2del n/a Distal 16p11.2 deletion (chr16:28,819,029–29,043,973,incl. SH2B1) de novo
8 16p11.2del n/a Proximal 16p11.2 deletion (chr16:29,563,985–30,107,008, not incl. SH2B1) de novo
9 mUPD14 (Temple syndrome) n/a Temple syndrome (caused by maternal uniparental disomy chromosome 14) n/a
10 mUPD14 (Temple syndrome) n/a Temple syndrome (caused by maternal uniparental disomy chromosome 14) n/a
11 Epigenetic error chr14 (Temple
syndrome)
n/a Temple syndrome (caused by imprinting defect on chromosome 14) n/a
12 Epigenetic error chr14 (Temple
syndrome)
n/a Temple syndrome (caused by imprinting defect on chromosome 14) n/a
13 MKKS (Bardet-Biedl
syndrome)
NM_018848.3 Compound heterozygous c.110A>G p.(Tyr37Cys), c.950_960del p.
(Gly317Aspfs�6)
P and M both
heterozygous
14 IFT74 (Bardet-Biedl syndrome) NM_025103.3 Compound heterozygous c.371_372del p.(Gln124Argfs�9), c.16850-1G>T
p.?
P and M both
heterozygous
15 MYT1L NM_015025.2 Heterozygous c.808del p.(Gln270Lysfs�11) de novo
16 POMC n/a 2p deletion (chr2:22.791.486–27.942.764), containing POMC) de novo
(Continued)
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Comparison of phenotype in patients with genetic obesity disorders and
patients without a singular underlying medical cause of obesity
Patients with genetic obesity disorders more often had an extreme early-onset of obesity <5
years (p = 0.04) and hyperphagia (p = 0.001) when compared to patients without a singular
underlying medical cause of obesity (Table 1, detailed p-values in S1 Table). Furthermore, the
presence of obesity in parents (p = 0.02) and psychosocial problems (determined by the
involvement of official authorities or DSM-V diagnosis; p = = 0.001) were less often present in
the genetic obesity group. No significant differences were found with respect to BMI SDS, sex,
socio-economic status z-score and family history of consanguinity or bariatric surgery (all
p>0.05; detailed p-values in S1 Table). When zooming in on patients with genetic obesity with
ID, they more often had short stature (p = 0.005), a history of neonatal feeding problems
(p = 0.003), a dysmorphic appearance and/or congenital anomalies (p<0.001), and less severe
obesity (lower BMI SDS; p<0.001) than patients without a singular underlying medical cause
of obesity. Extreme early-onset obesity <5 years and hyperphagia were not present more often
in the patients with genetic obesity disorders with ID (Table 1). With regard to height SDS,
patients with genetic obesity without ID had a higher height SDS than patients without a sin-
gular underlying medical cause of obesity, although this difference was not statistically signifi-
cant (p = 0.19). In contrast, patients with genetic obesity with ID had a significantly lower
height SDS (p = 0.004).
Comparison of patients with cerebral or medication-induced obesities with
other subgroups of patients
No assessed phenotype features were specifically present or absent in patients with cerebral or
medication-induced obesities (Table 1). However, on a group level, these patients had lower
height SDS than patients with genetic obesity disorders without ID or patients without under-
lying medical causes of the obesity.
Discussion
In this study, an extensive systematic diagnostic approach in a specialized obesity center estab-
lished an underlying medical cause of obesity in 19% of pediatric patients. These included
genetic obesity disorders (13%), medication-induced obesities (3%) and obesities due to cere-
bral injury (3%). To the best of our knowledge, this is the first study which reports the yield of
a broad diagnostic workup in a tertiary pediatric obesity cohort, focusing not only on genetic
obesity disorders but also on endocrine, medication-induced, and cerebral causes of obesity.
Table 2. (Continued)
Patient Gene/CNV Reference
transcript
Genetic alteration Inheritance
17 SPG11 (Spastic paraplegia 11) NM_025137.3 Compound heterozygous c.4534dup p.(Asp1512Glyfs�7), c.5867-?_6477+?
del p.? (deletion of exons 31–34
P and M both
heterozygous
18 VPS13B (Cohen syndrome) NM_017890.4 Compound heterozygous c.2911C>T p.(Arg971�), c.8697-2A>G p.? P and M both
heterozygous
CNV, copy number variation; SDS, standard deviation score; BMI, body mass index in kg/m2; ID, intellectual disability; M, mother; P, father; n.p., segregation analysis
not performed; PHP 1b, pseudohypoparathyroidism type 1b; PHP 1a, pseudohypoparathyroidism type 1a; PM, father of mother; MP, mother of father; n/a, not
applicable.
aimportant genetic risk factor contributing to severe early-onset obesity;
bsiblings.
https://doi.org/10.1371/journal.pone.0232990.t002
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Table 4. Clinical characteristics of patients diagnosed with a genetic obesity disorder without ID.
Gene/CNV MC4R LEPR POMC 6q16.3 deletion PCSK1 STX16 (PHP1b)
Genetic cause� Homoyzygous/
compound
heterozygous
disease-associated
variants
Heterozygous
disease-associated
variant
Homoyzygous/
compound
heterozygous disease-
associated variants
Heterozygous
disease-
associated
variant
6q16.3 deletion
incl. part of SIM1
Heterozygous
disease-
associated
variant
Heterozygous
disease-
associated
variant
Number of
patients
4 5 6 1 1 1 1
Age at diagnosis
in years, median
(range)
9.2 (1.6–15.4) 7.1 (2.2–15.3) 3.9 (0.7–14.8) 10.0 9.1 11.8 14.8
Clinical features at initial visit
Age in years,
range
6.5–15.4 2.5–15.3 0.7–17.7 10.0 9.1 12.2 17.2
Height SDS,
median (range)
+0.8 (+0.7 –+2.2) +2.1 (0.0 –+4.2) +1.0 (-1.2 –+2.2) -0.2 +3.0 -0.2 -0.1
Δ Height SDS vs
target height SDS,
median (range)
+1.4 (+0.7 –+3.2) +0.7 (-0.1 –+4.1) +1.2 (-1.3 –+1.5) -0.5 +2.4 +1.0 -0.6
BMI, median
(max)
34.0 (41.5) 27.9 (38.6) 35.3 (47.5) 28.2 36.8 32.9 31.4
BMI SDS, median
(max)
+4.3 (+5.2) +4.2 (+5.4) +4.6 (+8.9) +3.9 +4.4 +3.5 +2.9
Early-onset <5
years
3/4 5/5 6/6 Yes Yes Yes Yes
Hyperphagia 3/4 5/5 5/6 No Yes No Yes
ID 0/4 0/4 0/6 No No No No
History of
abnormal
neonatal feeding
behavior
Reduced satiety 3/4 No Reduced satiety 4/6 No No No Reduced satiety
1/1
Clinical features
characteristic of
the genetic obesity
disorder as
mentioned in the
Endocrine Society
Guideline
Hyperphagia 4/4 Hyperphagia 4/5 Extreme hyperphagia
5/6
Genetic obesity
syndrome not
mentioned in
guideline
Genetic obesity
syndrome not
mentioned in
guideline
Genetic obesity
syndrome not
mentioned in
guideline
Genetic obesity
syndrome not
mentioned in
guideline
Accelerated linear
growth 3/4
Accelerated linear
growth 3/5
Frequent infections 0/
6
Disproportionate
hyperinsulinemia 4/
4
Disproportionate
hyperinsulinemia 1/
5
Hypogonadotropic
hypogonadism 3/4c
Low/normal blood
pressure 1/4
Low/normal blood
pressure 4/4b
Mild hypothyroidism
2/6
Additional clinical
features
characteristic of
the genetic obesity
disorder
More severe
phenotype than
autosomal dominant
N/A Growth hormone
deficiency 1/6
Hyperphagia
(less severe than
autosomal
recessive POMC
deficiency) 0/1
Characteristics
depending on size
of deletion:
Intellectual
disability 0/1
Hyperphagia
(less severe than
autosomal
recessive PCSK1
deficiency) 0/1
PTH resistance
1/1;
Occasionally
partial TSH
resistance 1/1
Autism 0/1 Enhanced
intrauterine
growth 1/1
Behavioral
problems 0/1
Occasionally
mild
brachydactyly
1/1
Round facies 1/
1
(Continued)
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Previously, Reinehr et al. assessed the prevalence of endocrine causes and of specific genetic
causes, namely clinically identifiable syndromal causes and MC4R pathogenic variants in a
subgroup of their cohort. [7] Their study, performed in 1405 children and adolescents visiting
a specialized clinic for endocrinology and obesity, demonstrated an underlying disorder in 13
(1.7%) patients.
There are some explanations for our high diagnostic yield. First, our patients constitute a
tertiary pediatric obesity population with severe obesity who were referred because of a suspi-
cion of an underlying medical cause, or resistance to lifestyle interventions. Thus, we had a
higher a priori probability of finding underlying medical causes than in an unselected pediatric
obesity population. Nevertheless, we show that a broad systematic diagnostic workup is needed
to identify these diverse underlying causes of obesity. Secondly, medication use and cerebral/
hypothalamic injury were not mentioned in the evaluation of other cohorts, although they are
part of the recommended diagnostic workup of the ES guideline for pediatric obesity. [13] Fur-
thermore, the guideline mentions only antipsychotics as weight-inducing medication, but we
also considered specific antipsychotic or anti-epileptic drugs [37, 38] and prolonged use of cor-
ticosteroids [35, 36] as potential cause of obesity in individual patients, but only in the presence
of a temporal relationship with onset of obesity, objectified through comprehensive growth
chart analysis, and in the absence of other underlying medical causes of obesity or other plausi-
ble explanations for the sudden weight gain. Comprehensive growth chart analysis was also
supportive in the identification of patients with cerebral/hypothalamic injury as the cause of
their obesity in our cohort. Thus, future guidelines might benefit from adding growth chart
analysis as part of the diagnostic workup of pediatric obesity. Thirdly, intellectual disability
was present in 24% of patients, which increased the a priori probability of genetic obesity dis-
orders with ID. The last explanation for our high yield is the extensive genetic testing we per-
formed. Pathogenic variants in MC4R were the most frequently identified genetic cause of
obesity in our cohort (9/282 patients, 3.2%). This number is comparable to previous findings
in another Dutch tertiary pediatric cohort (2.1%) [40] and 1.6–2.6% in other non-consanguin-
eous pediatric cohorts screening for genetic obesity. [41, 42] However, in many studies, only
MC4R mutations or a small number of obesity-associated genes are tested. [7, 27, 40–43] In
our cohort, 13 genetic obesity disorders other than MC4R were present. Thus, this study shows
Table 4. (Continued)
Gene/CNV MC4R LEPR POMC 6q16.3 deletion PCSK1 STX16 (PHP1b)
Presence of
genetic alteration
in parents
2/4 both parents
heterozygous 2/4 n.
p.
3/5 inherited from
parent, 1/5 de novo,
1/5 n.p.
All parents
heterozygous
n.p. De novo Inherited from
mother
Inherited from
mother
Presence of
obesity in parents
who carry the
genetic alteration
Obesity present in
1/4 heterozygous
parents (known
reduced penetrance)
Obesity present in 1
/3 heterozygous
parents (known
reduced penetrance)
Obesity present in 3/
12 heterozygous
parents (unclear
association with
heterozygosity)
N/A N/A Obesity present
in heterozygous
mother
Obesity not
present in
heterozygous
mother
PHP1b, pseudohypoparathyroidism type 1b; SDS, standard deviation score; BMI, body mass index; ID, intellectual disablility; BP, blood pressure; N/A, not applicable;
PTH, parathyroid hormone; TSH, thyroid-stimulating hormone; n.p., not performed.
�exact genetic alterations are listed in Table 2.
ahistory of abnormal neonatal feeding behavior, i.e. reduced satiety and/or hypotonia/feeding problems;
bIn 1 patient, BP could not be measured due to unrest.
cIn 2 prepubertal patients not (yet) detectable.
https://doi.org/10.1371/journal.pone.0232990.t004
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that extensive genotyping can highly augment the diagnostic yield when performed in similar
pediatric obesity cohorts. The extent to which heterozygous mutations/CNV in PCSK1 and
POMC are involved in monogenic obesity remains a point of discussion. Association studies
clearly demonstrate that these rare variants contribute to a highly increased risk for obesity.
[27, 39] Moreover, identifying these patients is of clinical importance for patient-tailored treat-
ment as clinical trials with MC4R-agonist setmelanotide will be conducted, as it is hypothe-
sized that these patients will have reduced MC4R functioning. [44]
We did not identify patients with an endocrine disorder as the cause of obesity. None of the
patients were diagnosed with Cushing’s syndrome. Pediatric Cushing’s syndrome is extremely
rare, [45] and patients are often referred due to impaired growth velocity and abnormal labo-
ratory results. [13] Therefore, in contrast to adults, these patients are not primarily referred to
obesity clinics. Retrospective analysis of ICD-10 codes for Cushing’s syndrome in the central
hospital registries at both participating centers during the entire study period (2015–2018)
showed four diagnoses of pediatric Cushing’s syndrome in these years; none of these four
patients developed severe obesity. Importantly, PWS, the most common genetic obesity disor-
der with ID, was not identified in our cohort. This can be explained by the fact that in Dutch
pediatric practice, PWS is often diagnosed during the neonatal period due to the typical hypo-
tonia and feeding problems and after diagnosis, clinical care is transferred to specialized PWS
expertise centers.
The second aim of our study was to present the phenotype of patients with underlying med-
ical causes and investigate whether they can be distinguished from patients without underlying
medical causes. We therefore performed the comprehensive diagnostic workup in all patients.
In daily clinical practice with lower a priori probability of underlying medical causes, it is com-
plex to determine for whom these diagnostics should be performed. According to literature,
one of the most important features to help distinguish these patients is their stature. Reinehr
et al. reported that short stature had a high sensitivity for underlying causes of obesity in their
cohort. [7] In our study, patients with genetic obesity disorders associated with ID, and
patients with cerebral and medication-induced obesities in our cohort indeed had lower height
SDS than expected based on the fact that obesity is associated with taller stature. [46] However,
most of these patients did not fulfill the definition for short stature. [19] Unsurprisingly, cardi-
nal features of genetic obesity disorders, namely early onset of obesity (<5 years) and hyper-
phagia, were more often present in patients with genetic obesity, but only when ID was not
present. On the other hand, patients with genetic obesity disorders with ID more often had a
history of neonatal feeding problems and congenital anomalies or dysmorphic features. Thus,
presence of these features should lead to consideration to perform additional diagnostics. Con-
trary to expectations BMI SDS was not significantly higher in patients with genetic obesity
compared to patients without underlying medical causes. A possible explanation is that sever-
ity of obesity increases the probability of being referred to a pediatric obesity center regardless
of whether genetic obesity is diagnosed. Important factors that were more frequently present
in the patients without underlying medical causes were psychosocial problems (DSM-5 diag-
nosis or involvement of authorities such as child protective services). These psychosocial prob-
lems might contribute to developing a higher BMI SDS. [47] On group level, we did not find
evidence for significant differences in socio-economic status scores between patients with
genetic obesity and patients without underlying medical causes, but individual differences in
socio-economic factors and obesogenic environments might also play a role. Interestingly,
parents of children with a genetic obesity disorder more often had no obesity than parents of
children without an underlying cause. This sounds counterintuitive for hereditary obesity dis-
orders, but can be explained by the fact that most of the genetic aberrations in our cohort had
occurred de novo or had an autosomal recessive inheritance pattern. Thus, negative family
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history of obesity could therefore suggest a genetic obesity disorder. In conclusion, we show
that several phenotypic features differed significantly between patients with and without
underlying medical causes of obesity, but no feature was specific. Thus, a broad diagnostic
workup is warranted in patients with a high suspicion of an underlying medical cause of obe-
sity, e.g., in cases with early-onset obesity, hyperphagia, relatively low height SDS (especially in
the presence of ID) and presence of sudden weight changes objectified through comprehensive
growth chart analysis.
Treatment of multifactorial disorders such as obesity is complex. In our approach, all
patients received a multidisciplinary treatment advice tailored to their personal needs, includ-
ing personalized dietary and physical activity advice (Fig 2). Furthermore, a monitoring and
follow-up plan was developed for every patient. Local health care providers, including child
health clinic physicians, general practitioners, general pediatricians, and psychologists, were
contacted for local implementation of the care plan. In cases with severe hyperphagia, parental
support by an educational therapist was offered to cope with the child’s behavior. Rehabilita-
tion physicians were consulted when obesity interfered with performance of daily activities
such as walking. [10]
Establishing a main underlying cause of obesity can improve personalized treatment. [34]
In all our 54 patients with an underlying medical cause, counseling about the diagnosis was
given. This included advice pertaining to bariatric surgery, which has unclear long-term suc-
cess rates for patients with underlying medical causes. [43, 48] Patients with genetic obesity
were counseled by a clinical geneticist regarding inheritance, associated medical problems and
reproductive decisions. Hormonal supplementation was started in case of hormonal deficien-
cies associated with specific genetic obesity disorders (such as growth hormone treatment in
cases with leptin receptor deficiency). [49] In cases of syndromic obesity, the patients were
evaluated for associated organ abnormalities or referred for disease-specific surveillance. [13,
25–32] In patients with cerebral/hypothalamic injury as cause of obesity and hyperphagia, dex-
amphetamine treatment was considered. [50] In patients with medication-induced obesity,
evaluation of necessity and alternatives for the weight-inducing medication took place in col-
laboration with the prescribing physician. Follow-up studies are necessary to evaluate the dif-
ferent individual responses to these treatment options. Interesting novel developments are
clinical trials with MC4R-agonists in patients with leptin-melanocortin pathway deficiencies,
e.g. POMC and LEPR deficiency, [44] and glucagon-like peptide 1 (GLP-1) agonists for adoles-
cents with obesity. [51] These GLP-1 agonists might also be a future treatment option for
patients with genetic obesity disorders, as they have been shown to be equally as effective in
adults with heterozygous MC4R mutations compared to adults without. [52] Recently, it was
suggested that a subgroup of patients with severe early-onset obesity might have relative leptin
deficiency and therefore might benefit from recombinant leptin administration. [53] However,
the (long-term) effects of these new potential treatment options remain to be investigated.
Strengths and limitations
A major strength of our study is the use of a systematic diagnostic strategy in all patients inves-
tigating all medical causes of obesity mentioned in the current international guideline. [13]
Moreover, we performed genetic diagnostics in all patients, and further genetic tests when
clinically indicated. Furthermore, our relatively high diagnostic yield enabled us to describe
the clinical phenotypes of a large number (n = 54) of patients with underlying causes of obesity
from a relatively small patient cohort of 282 patients. When performing research in a diagnos-
tic setting, one faces logistical limitations. During our study, three different versions of the
diagnostic obesity-associated gene panel test were successively available for clinical use in The
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Netherlands. Importantly, in all used gene panels at least the most important and well-known
obesity-associated genes were tested, including among others LEP, LEPR, MC4R, POMC,
PCSK1, ALMS1, GNAS, SH2B1, and SIM1. A strength of our diagnostic setting is that we fol-
lowed the current ACMG guidelines for variant calling, leading to stringent selection of only
pathogenic and likely pathogenic variants for which evidence from validated functional studies
and from control populations has already been incorporated. [24] Children and adolescents
with a high suspicion of a genetic cause with negative genetic testing results should be viewed
as ‘unsolved cases’, for which current genetic tests are not yet able to pinpoint a diagnosis. As
the field of obesity genetics is progressing rapidly, very recently discovered obesity genes were
not present in the used diagnostic gene panels. [54] Incorporating these obesity genes might
have resulted in an even higher diagnostic yield. Moreover, newer techniques such as whole-
genome sequencing will become more easily accessible and affordable in clinical practice and
will likely lead to more genetic obesity diagnoses.
We understand that our comprehensive approach is not feasible in every clinical setting,
but our data suggest that it has added value for selected patient groups. Prospective studies
looking at predictors for underlying medical causes of obesity are necessary but are difficult to
establish because of the rarity of these disorders and overlap with common obesity. Interna-
tional collaboration in large multicenter studies using a similar standardized comprehensive
approach are required.
Conclusion
In conclusion, we show that a large variety of underlying medical obesity diagnoses can be
established in pediatric patients with obesity in tertiary care setting when using a comprehen-
sive diagnostic workup. Investigating endocrine, genetic, cerebral and medication-induced
causes of obesity is needed for these patients to facilitate disease-specific and patient-tailored
treatment. Further studies on predictors of underlying medical causes of obesity are needed to
improve identification of these patients.
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